10,250 Shares in Nutex Health Inc. $NUTX Purchased by Bank of America Corp DE

Key Points

• Bank of America purchased 10,250 Nutex Health shares in the second quarter, valued at approximately $1.75 million. Other institutions, including BlackRock and Winmill & Co., also established sizable positions, though institutional investors collectively own just 5.32% of the stock.
• Analyst sentiment remains generally positive: Nutex Health has an average “Buy” rating and a $317.50 consensus price target. Lake Street Capital raised its target to $310, while Zacks upgraded the stock to “Strong Buy.”
• Nutex Health shares opened at $212.31, near their 12-month high of $224.28, after the company reported quarterly EPS of $9.38—well above the $4.95 analyst consensus. Director Scott Saunders separately sold 203 shares, reducing his holdings by 33.67%.

Bank of America Corp DE purchased a new stake in Nutex Health Inc. (NASDAQ:NUTX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 10,250 shares of the company's stock, valued at approximately $1,752,000. Bank of America Corp DE owned 0.15% of Nutex Health as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NUTX. BlackRock Inc. purchased a new position in shares of Nutex Health in the 2nd quarter valued at about $69,612,000. Winmill & CO. Inc. acquired a new stake in Nutex Health in the second quarter valued at approximately $11,168,000. Empowered Funds LLC purchased a new position in Nutex Health in the first quarter worth approximately $3,084,000. SG Americas Securities LLC lifted its stake in Nutex Health by 3,232.6% in the first quarter. SG Americas Securities LLC now owns 30,360 shares of the company's stock worth $2,885,000 after acquiring an additional 29,449 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Nutex Health in the second quarter worth approximately $3,956,000. 5.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NUTX has been the subject of a number of analyst reports. Zacks Research upgraded shares of Nutex Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 24th. Lake Street Capital restated a "buy" rating and issued a $310.00 price target (up from $235.00) on shares of Nutex Health in a research note on Tuesday, August 11th. Weiss Ratings raised Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, July 28th. B. Riley Financial reaffirmed a "buy" rating on shares of Nutex Health in a report on Friday, September 4th. Finally, Wall Street Zen cut Nutex Health from a "buy" rating to a "hold" rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $317.50.

Insider Activity

In related news, Director Scott Saunders sold 203 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $214.25, for a total transaction of $43,492.75. Following the transaction, the director owned 400 shares in the company, valued at $85,700. This trade represents a 33.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 44.68% of the stock is currently owned by company insiders.

Nutex Health Trading Up 0.3%

Shares of Nutex Health stock opened at $212.31 on Friday. The company has a fifty day simple moving average of $187.22 and a 200-day simple moving average of $151.04. Nutex Health Inc. has a 12-month low of $83.99 and a 12-month high of $224.28. The company has a current ratio of 5.00, a quick ratio of 4.96 and a debt-to-equity ratio of 0.59. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 8.34 and a beta of 0.55.

Nutex Health (NASDAQ:NUTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, beating analysts' consensus estimates of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The firm had revenue of $210.75 million during the quarter, compared to analysts' expectations of $215.03 million. On average, equities analysts forecast that Nutex Health Inc. will post 27.58 EPS for the current fiscal year.

Nutex Health Company Profile

Nutex Health Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, outpatient facilities and physician practices. The company focuses on delivering emergency, inpatient and outpatient care through community-based healthcare facilities, including micro-hospitals designed to provide essential hospital services in convenient local settings.

Its services may include emergency medicine, primary care, specialty care, diagnostic testing, imaging, laboratory services and other ancillary healthcare offerings.

Want to see what other hedge funds are holding NUTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nutex Health Inc. (NASDAQ:NUTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.